

Respiratory Disorder

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

Trial Status
Completed

Trial Runs In
14 Countries

Trial Identifier
NCT03099187 2016-002744-17
MA39189

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03099187 2016-002744-17 MA39189
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 85 Years

Healthy Volunteers
No
